Global innovative drug development
based on creation & know-how



BiSiChem is a leading biotechnology company focused on the discovery and development of promising targets,
such as well-validated small molecule drug targets, for immuno-oncology, targeted cancer and CNS therapy.

Our goal is to develop the breakthrough cancer therapy as innovative first in class therapeutic candidates.
We intend to complete successfully this goal through the following strategies.

Understanding global market demand and market value.
Also, BiSiChem team has the ability to bring discovery candidates, the pioneering networks,
expertise, and discovery platform.


  • 2017.08

    BiSiChem Co., Ltd

  • 2017.11 Head office relocation to Pangyo Start-up Campus

    - Set the foundation for full-scale discovery and development of new drugs

  • 2018.05

    Construction of
    BiSiChem's R&D Center

  • 2018.10 Began development of BSC-2300

    - Signed a joint discovery and development agreement with biopharmaceutical company in the US

  • 2019.01 BSC-1401 patent application submitted in the USPTO

    - An innovative drug candidate under development as a targeted cancer and other novel indication

  • 2019.04

    Third-party allocation paid-in capital increase (₩10B)